Is Celcuity (CELC) Undervalued After Its Q3 Loss Raised Fresh Questions?

Celcuity (CELC) drew fresh attention on November 5 after reporting third quarter results that showed a wider net loss and higher basic loss per share from continuing operations compared with the same period in 2025.

Celcuity’s share price closed at US$66.79 on November 5, and that move came after a Q3 update that expanded the reported net loss and basic loss per share, which likely shifted how traders view short term risk around the biotech’s cash needs and trial progress.

Even with a 1 day share price return of 4.29% after the numbers, the stock is down 26.43% on a 90 day share price basis and 33.58% year to date. Total shareholder return over five years is up 282.09%, so long term momentum remains strong but has faded recently as sentiment cools after a very large three year total shareholder return of more than 5x.

Spot fresh moves in Celcuity, then compare them with hand picked biotech and high quality companies across the market using the 19 high quality undiscovered gems.

Celcuity now trades at a sharp discount to both analyst targets and one intrinsic value estimate, even after the earnings day bounce. Is that an opportunity, or a fair reflection of rising concern about cash burn and trial risk?

Most Popular Narrative: 56% Undervalued

Celcuity’s analyst consensus Narrative on Simply Wall St flags a fair value of $152.72 a share, which sits well above the last close at $66.79. This frames the Q3 pullback as a sizeable discount tied to execution risk rather than completed outcomes.

Recent financing activities that resulted in about US$455m of cash, cash equivalents and short term investments and access to a US$500m term loan facility give Celcuity funding through 2027. This supports ongoing R&D, launch build out and commercial infrastructure that will influence operating expenses and the path to potential earnings leverage.

See why 5 investors see Celcuity as 56% undervalued.

Result: Fair Value of $152.72 (UNDERVALUED)

Still, Celcuity’s heavy R&D spending and ongoing net losses, along with clinical and regulatory uncertainty around gedatolisib, could quickly challenge that undervalued narrative.

Find out about the key risks to this Celcuity narrative.

Next Steps

Mixed signals around Celcuity’s valuation, funding runway and trial risk can stir strong reactions, so move quickly, review the details and weigh both the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Celcuity?

Do not stop your research with Celcuity. Broaden your watchlist now with a few focused stock ideas that match different risk, income and quality profiles.

• Target potential mispricing by scanning companies that combine quality fundamentals with discounted valuations using the 40 high quality undervalued stocks.
• Prioritize staying power by checking out businesses with strong finances through the list of solid balance sheet and fundamentals (25 results).
• Dial down portfolio stress by hunting for companies with steadier profiles and resilient track records via the 31 resilient stocks with low risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com